ArticleAnnals of gastroenterology

Panitumumab in combination with modified docetaxel/cisplatin/5-fluorouracil as first-line treatment in gastric and gastroesophageal junction adenocarcinomas: a multicenter phase II study by the Hellenic Oncology Research Group.

Nikolaos Kentepozidis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.